NCT07154706Phase 3Recruiting

Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)

Study sponsor: Nuvation Bio Inc. · NUVB

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2030-08-30Estimated
Enrollment · participants180Estimated
Source updated2026-05-19Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.